Epigenomics AG (EPGNF)
USD 0.79
(0.09%)
USD 0.79
(0.09%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.17 Million EUR | 65.34% |
| 2022 | -12.05 Million EUR | -411.94% |
| 2021 | -2.35 Million EUR | 79.75% |
| 2020 | -11.62 Million EUR | 20.76% |
| 2019 | -14.67 Million EUR | -13.79% |
| 2018 | -12.89 Million EUR | -25.33% |
| 2017 | -10.28 Million EUR | 16.43% |
| 2016 | -12.31 Million EUR | -32.9% |
| 2015 | -9.26 Million EUR | -10.51% |
| 2014 | -8.38 Million EUR | -15.02% |
| 2013 | -7.28 Million EUR | 39.88% |
| 2012 | -12.12 Million EUR | 20.48% |
| 2011 | -15.24 Million EUR | -33.16% |
| 2010 | -11.44 Million EUR | -12.05% |
| 2009 | -10.21 Million EUR | 19.86% |
| 2008 | -12.75 Million EUR | 5.58% |
| 2007 | -13.5 Million EUR | 14.32% |
| 2006 | -15.76 Million EUR | -254.01% |
| 2005 | 10.23 Million EUR | 3.71% |
| 2004 | 9.86 Million EUR | 57.36% |
| 2003 | 6.27 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 FY | -4.17 Million EUR | 65.34% |
| 2023 Q4 | 2.16 Million EUR | 0.0% |
| 2023 Q2 | -2.63 Million EUR | 53.54% |
| 2023 Q1 | -5.66 Million EUR | 13.67% |
| 2023 Q3 | 2.16 Million EUR | 182.15% |
| 2022 Q3 | -1.55 Million EUR | -20.53% |
| 2022 Q1 | -2.64 Million EUR | -53.81% |
| 2022 Q4 | -6.56 Million EUR | -323.68% |
| 2022 FY | -12.05 Million EUR | -411.94% |
| 2022 Q2 | -1.28 Million EUR | 51.42% |
| 2021 Q3 | 2.85 Million EUR | 223.38% |
| 2021 Q4 | -1.72 Million EUR | -160.39% |
| 2021 FY | -2.35 Million EUR | 79.75% |
| 2021 Q1 | -1.17 Million EUR | 54.16% |
| 2021 Q2 | -2.31 Million EUR | -96.76% |
| 2020 FY | -11.62 Million EUR | 20.76% |
| 2020 Q3 | -2.73 Million EUR | 18.44% |
| 2020 Q1 | -2.96 Million EUR | 22.94% |
| 2020 Q2 | -3.35 Million EUR | -13.15% |
| 2020 Q4 | -2.56 Million EUR | 6.43% |
| 2019 FY | -14.67 Million EUR | -13.79% |
| 2019 Q1 | -3.31 Million EUR | 17.73% |
| 2019 Q2 | -4.66 Million EUR | -40.84% |
| 2019 Q3 | -2.84 Million EUR | 39.05% |
| 2019 Q4 | -3.84 Million EUR | -35.34% |
| 2018 Q3 | -2.03 Million EUR | 20.95% |
| 2018 FY | -12.89 Million EUR | -25.33% |
| 2018 Q1 | -3.25 Million EUR | -77.3% |
| 2018 Q2 | -2.57 Million EUR | 20.68% |
| 2018 Q4 | -4.02 Million EUR | -97.6% |
| 2017 FY | -10.28 Million EUR | 16.43% |
| 2017 Q1 | -2.69 Million EUR | -69.48% |
| 2017 Q3 | -1.19 Million EUR | 73.72% |
| 2017 Q2 | -4.56 Million EUR | -69.44% |
| 2017 Q4 | -1.83 Million EUR | -52.88% |
| 2016 Q2 | -3.48 Million EUR | 24.65% |
| 2016 FY | -12.31 Million EUR | -32.9% |
| 2016 Q4 | -1.58 Million EUR | 39.24% |
| 2016 Q3 | -2.61 Million EUR | 24.96% |
| 2016 Q1 | -4.62 Million EUR | -361.12% |
| 2015 Q3 | -2.53 Million EUR | 1.48% |
| 2015 Q4 | -1 Million EUR | 60.36% |
| 2015 Q2 | -2.56 Million EUR | 18.84% |
| 2015 Q1 | -3.16 Million EUR | -5.71% |
| 2015 FY | -9.26 Million EUR | -10.51% |
| 2014 Q1 | -2 Million EUR | 5.39% |
| 2014 FY | -8.38 Million EUR | -15.02% |
| 2014 Q4 | -2.99 Million EUR | -68.81% |
| 2014 Q3 | -1.77 Million EUR | -9.72% |
| 2014 Q2 | -1.61 Million EUR | 19.2% |
| 2013 Q2 | -1.6 Million EUR | 6.13% |
| 2013 Q3 | -1.85 Million EUR | -15.43% |
| 2013 Q4 | -2.11 Million EUR | -13.96% |
| 2013 FY | -7.28 Million EUR | 39.88% |
| 2013 Q1 | -1.71 Million EUR | 36.43% |
| 2012 Q2 | -3.44 Million EUR | -49.59% |
| 2012 FY | -12.12 Million EUR | 20.48% |
| 2012 Q1 | -2.3 Million EUR | 48.83% |
| 2012 Q3 | -3.68 Million EUR | -7.15% |
| 2012 Q4 | -2.69 Million EUR | 26.98% |
| 2011 FY | -15.24 Million EUR | -33.16% |
| 2011 Q1 | -2.74 Million EUR | 8.85% |
| 2011 Q2 | -2.97 Million EUR | -8.58% |
| 2011 Q3 | -5.03 Million EUR | -69.14% |
| 2011 Q4 | -4.49 Million EUR | 10.63% |
| 2010 Q1 | -2.6 Million EUR | 17.69% |
| 2010 Q4 | -3 Million EUR | 0.13% |
| 2010 Q3 | -3.01 Million EUR | -6.44% |
| 2010 Q2 | -2.82 Million EUR | -8.56% |
| 2010 FY | -11.44 Million EUR | -12.05% |
| 2009 Q3 | -2.28 Million EUR | 6.92% |
| 2009 FY | -10.21 Million EUR | 19.86% |
| 2009 Q1 | -2.31 Million EUR | 0.0% |
| 2009 Q2 | -2.45 Million EUR | -6.27% |
| 2009 Q4 | -3.16 Million EUR | -38.45% |
| 2008 FY | -12.75 Million EUR | 5.58% |
| 2007 FY | -13.5 Million EUR | 14.32% |
| 2006 FY | -15.76 Million EUR | -254.01% |
| 2005 FY | 10.23 Million EUR | 3.71% |
| 2004 FY | 9.86 Million EUR | 57.36% |
| 2003 FY | 6.27 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | -236.275% |
| Arrayit Corporation | -3.62 Million USD | -15.294% |
| Atlantic International Corp. | -5.73 Million USD | 27.143% |
| Biocept, Inc. | -31.98 Million USD | 86.941% |
| Bioqual, Inc. | -19.63 Thousand USD | -21167.639% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | -440.903% |
| DermTech, Inc. | -103.73 Million USD | 95.974% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 100.168% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 79.949% |
| iMD Companies, Inc. | -175.44 Thousand USD | -2280.527% |
| IDenta Corp. | -1499.00 USD | -278521.681% |
| Interpace Biosciences, Inc. | 2.8 Million USD | 248.949% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 10894.88% |
| InVitro International | -25.33 Thousand USD | -16382.651% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | 41.357% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -7087.051% |
| Medical Imaging Corp. | -819.48 Thousand USD | -409.657% |
| NovelStem International Corp. | -3.52 Million USD | -18.457% |
| Optigenex Inc. | 1.39 Million USD | 400.29% |
| PharmChem, Inc. | 973.14 Thousand USD | 529.179% |
| Proteome Sciences plc | -1.62 Million USD | -157.652% |
| Response Genetics, Inc | -21.37 Million USD | 80.462% |
| Rennova Health, Inc. | -1.4 Million USD | -196.306% |
| RushNet, Inc. | -684.7 Thousand USD | -509.976% |
| ScreenPro Security Inc. | -2.59 Million USD | -61.105% |
| Stella Diagnostics Inc. | -11.42 Million USD | 63.45% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | 46.087% |
| Todos Medical Ltd. | -9.74 Million USD | 57.155% |